Inactive Instrument

News CELLCEUTIX OTC Bulletin Board

Stocks

CTIX

US15115V1017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

01/24/01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
06/23/06	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

All News

Mentions Relevance

01/24/01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
06/23/06	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI
21/23/21	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI
28/23/28	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	CI
28/23/28	Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024	AQ
21/23/21	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	CI
21/23/21	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	AQ
05/23/05	Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing	AQ
15/23/15	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
17/23/17	Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications	AQ
15/23/15	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers	AQ
15/23/15	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	CI
23/23/23	Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission	AQ
16/23/16	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
16/23/16	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
09/23/09	Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement	AQ
05/23/05	INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)	AQ
14/22/14	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis	AQ
13/22/13	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis	AQ
13/22/13	Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	CI
28/22/28	Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family	AQ
16/22/16	Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference	AQ
11/22/11	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
11/22/11	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
27/22/27	Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'	AQ